![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Moleculin’s Annamycin Gains FDA Orphan Drug Status
Moleculin’s Annamycin Gains FDA Orphan Drug Status
![FDA Logo device green](https://www.fdanews.com/ext/resources/test/Device_Images/fda-logo.gif?t=1614205361&width=430)
January 4, 2021
Moleculin’s anthracycline chemotherapy drug annamycin has earned its second Orphan Drug designation from the FDA, this time for the treatment of soft-tissue sarcomas.
The Houston, Tex.-based biotech previously earned Orphan Drug designation for annamycin for treating relapsed or refractory acute myeloid leukemia. The drug is designed to avoid multidrug-resistance mechanisms with little to no cardiotoxicity.
The agency recently gave Moleculin the go-ahead to begin a phase 1b/2 clinical trial of annamycin for patients with soft-tissue sarcoma that has metastasized to the lungs after first-line therapy.
Upcoming Events
-
21Oct